within Pharmacolibrary.Drugs.ATC.J;

model J01DD63
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.1666666666666666e-05,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0035,
    k12             = 0.6,
    k21             = 0.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DD63</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ceftriaxone is a third-generation cephalosporin antibiotic often combined with a beta-lactamase inhibitor to enhance activity against beta-lactamase-producing bacteria. This combination is used in the treatment of various bacterial infections, including complicated urinary tract infections, respiratory tract infections, intra-abdominal infections, and sepsis. The combination with a beta-lactamase inhibitor is not currently approved or widely available, and products under this ATC code (J01DD63) are investigational or regionally available.</p><h4>Pharmacokinetics</h4><p>No existing publication reports human pharmacokinetics for ceftriaxone and beta-lactamase inhibitor combination as described by ATC J01DD63. Values provided are estimated based on standard ceftriaxone PK repeated for the combination.</p><h4>References</h4><ol><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2014). Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. <i>Drugs</i> 74(1) 31–51. DOI:<a href=&quot;https://doi.org/10.1007/s40265-013-0168-2&quot;>10.1007/s40265-013-0168-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24352909/&quot;>https://pubmed.ncbi.nlm.nih.gov/24352909</a></p></li><li><p>Kokai-Kun, JF, et al., &amp; Sliman, J (2017). The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies. <i>Antimicrobial agents and chemotherapy</i> 61(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02197-16&quot;>10.1128/AAC.02197-16</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28052855/&quot;>https://pubmed.ncbi.nlm.nih.gov/28052855</a></p></li><li><p>Payasi, A, et al., &amp; Bhatnagar, A (2010). Pharmacokinetic study of sulbactomax. <i>The Journal of toxicological sciences</i> 35(4) 459–464. DOI:<a href=&quot;https://doi.org/10.2131/jts.35.459&quot;>10.2131/jts.35.459</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20686332/&quot;>https://pubmed.ncbi.nlm.nih.gov/20686332</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DD63;
